期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 151, 期 -, 页码 686-704出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2018.03.079
关键词
-
资金
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [305385/2014-3, PVE 401193/2014-4, 477346/2013-8, 110818/2016-4, 305741/2017-9, 404466/2016-8]
- FAPEMIG [APQ-02478-14]
- Programa Pesquisador Mineiro [PPM-00638-16]
- Rede de Pesquisa e Inovacao para Bioengenharia de Nanossistemas [RED-00282-16]
- INCT-Catalise
- CAPES/DAAD [99999.008126/2015-01]
- CAPES
Morita-Baylis-Hillman acetates and alpha-bromonitroalkenes have been employed in cascade reactions with lawsone and 2-aminonaphthoquinone for the one-pot synthesis of heterocycle fused quinonoid compounds. The reactions reported here utilized the 1,3-binucleophilic potential of hydroxy- and aminonaphthoquinones and the 1,2/1,3-bielectrophilic potential of bromonitroalkenes and Morita-Baylis Hillman acetates for the synthesis of pyrrole and furan fused naphthoquinones. The synthesized compounds were evaluated against HCT-116 (human colon carcinoma cells), PC3 (human prostate cancer cells), HL-60 (human promyelocytic leukemia cells), SF295 (human glioblastoma cells) and NCI-H460 (human lung cancer cells) and exhibited antitumor activity with IC50 values as low as < 2 mu M. Selected compounds were also evaluated against OVCAR-8 (ovary), MX-1 (breast) and JURKAT (leukemia) cell lines. The cytotoxic potential of the quinones evaluated was also assayed using non-tumor cells, exemplified by peripheral blood mononuclear (PBMC) and L929 cells. (C) 2018 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据